skip to Main Content

Brigham and Women’s Hospital Biorepositories:

BRASS is a prospective observational study of >1500 patients with rheumatoid arthritis at the Robert Breck Brigham Arthritis Clinic in Boston, MA. The study began enrollment in March 2003 and plans to have a total of 20 year of follow-up.  Annual study visits occur in coordination with clinical appointments to obtain validated measures of RA disease activity, patient reported outcomes, and blood samples. Hand radiographs are taken every 2-3 years with Sharp Score data available on over 2800 x-rays. Every six months, subjects are mailed questionnaires inquiring about functional status, medication changes, healthcare utilization, RA flares, and socioeconomic status.

  • Principal Investigators: Dr. Nancy Shadick and Dr. Michael Weinblatt
  • Disease: rheumatoid arthritis
  • Samples available: DNA, RNA, plasma, serum, EMR data (sociodemographics, comorbidities, medications, and laboratory values), and genotypes
  • Detailed survey measures available: RA disease activity (DAS28, CDAI, RADAI), structural joint disease (Sharp van der Heijde score), functional status (MD-HAQ, EQ-5D), patient-reported outcomes (SF-12, PHQ-9, MHI-5, MOS Sleep Scale), DMARD changes, morning stiffness, sleep, flares, infections, and pain among others
  • Re-contact and prospective recruitment is available
  • Number of subjects with samples: >1590 as of August 27, 2020

PROSET-HD is a repository of peripheral blood mononuclear cells (PBMC) from > 400 patients with rheumatic diseases as well as non-inflammatory controls.

  • Principal Investigators: Dr. Michael Brenner and Dr. Deepak Rao
  • Diseases: rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, giant cell arteritis, psoriatic arthritis, juvenile idiopathic arthritis, polymyalgia rheumatica, spondyloarthritis
  • Samples available: PBMCs and EMR data (sociodemographics, comorbidities, medications, and laboratory values), including diagnosis, medications, CRP, RF/CCP, ANA, CDAI
  • Re-contact and prospective recruitment is available
  • Number of samples: >440 as of July 7, 2016

The BWH Division of Rheumatology, Immunology and Allergy have maintained an extensive repository of > 2800 samples obtained by clinical discards from the rheumatology clinic.  Consented patients donate blood and synovial samples as well as discarded samples after arthrocentesis and joint replacement surgery.

  • Principal Investigator: Dr. Peter Nigrovic
  • Diseases: rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, gout, pseudogout, psoriatic arthritis
  • Healthy controls available
  • Samples Available: DNA, plasma, serum, cells, synovial fluid, and joint tissue
  • Re-contact is available for some patients
  • Number of samples: >2848 as of July 7, 2016

In this study, synovial biopsy is performed by investigators using direct ultrasonographic guidance. Participants are research volunteers with or without active inflammatory arthritis. Blood samples and potentially synovial fluid samples are also obtained concurrently.

  • Principal Investigator: Dr. Derrick Todd
  • Diseases: rheumatoid arthritis, inflammatory arthritis
  • Control: Healthy controls, when available
  • Samples available: DNA, plasma, cells, synovial fluid, synovial tissue, and EMR data (sociodemographics, comorbidities, medications, and laboratory values)
  • Number of samples: 2

This repository includes samples from patients with psoriasis and psoriatic arthritis including plasma, PBMCs, DNA, and RNA as well as skin biopsies of psoriatic plaques.

  • Principal Investigators: Dr. Joseph Merola
  • Diseases: psoriasis and psoriatic arthritis
  • Healthy controls available
  • Samples available: DNA, plasma, cells, synovial tissue and, survey data
  • Prospective recruitment is available
  • Number of samples: >420 as of July 7, 2016

The BWH SLE Biobank, established in 2008, has enrolled >250 patients with systemic lupus erythematosus and samples are banked at the Broad Institute.  Clinical information, including lupus disease manifestations, treatment, and disease duration are available.

  • Principal Investigator: Dr. Karen Costenbader
  • Disease: systemic lupus erythematosus
  • Samples available: DNA, plasma, whole blood, EMR data (date of diagnosis, past medications, recent and past laboratories, clinical manifestations and organ involvement, lupus serologies, disease activity and organ damage), and survey data(demographic data, past medical history, family history, medications, allergies, exercise, medication adherence, smoking, alcohol intake, and other recent exposures)
  • Number of samples: >250 as of August 27, 2020

Boston Children’s Hospital Biorepositories:

This repository consists of samples from children with newly-diagnosed juvenile idiopathic arthritis recruited through the Boston Children’s Hospital rheumatology clinic.  Where available, discarded synovial fluid samples are also collected from children undergoing a therapeutic and/or diagnostic joint aspiration.

  • Principal Investigator: Dr. Peter Nigrovic
  • Disease: juvenile idiopathic arthritis
  • Samples available: DNA, RNA (Tempus, on a subset), serum, PBMCs (on a subset) and open access to medical record data
  • Healthy controls available
  • Re-contact is available
  • Number of samples: >220 as of July 7, 2016

This repository consists of samples from children with any rheumatic disease, or control non-inflammatory patients, recruited through the Boston Children’s Hospital rheumatology clinic.

  • Principal Investigators: Dr. Peter Nigrovic and Dr. Lauren Henderson
  • Disease: JIA, pediatric SLE, juvenile dermatomyositis, and PFAPA
  • Healthy controls available
  • Samples available: DNA, RNA, serum, PBMCs, and open access to medical record data. Where available, synovial fluid samples paired with blood are also collected from JIA patients.
  • Re-contact is available
  • Number of samples: >250 as of July 7, 2016

JBC members will have access to a repository of over 600 healthy serum and/or plasma samples collected by through various mechanisms which include discarded samples, consented samples recruited via the healthy pediatric DNA cohort and consented patients seen in the Boston Children’s Hospital rheumatology clinic for non-inflammatory disease.

  • Principal Investigator: Dr. Peter Nigrovic
  • Samples available: plasma and serum
  • No re-contact
  • Number of samples: >690 as of July 7, 2016

This Boston Children’s Hospital’s institutional biorepository provides investigators access to precious pediatric biospecimens, while harmonizing the collection of clinical and research samples from children to limit the number of procedures that children undergo for research.

  • Principal Investigator: Dr. Florence Bourgeois
  • Samples available: 1) all discarded specimens collected in the process of routine clinical care, including blood, plasma, cerebrospinal fluid, urine, biopsies, aspirates, and tissue specimens from any organ; 2) Research blood specimen for DNA extraction; and 3) all clinical data available through the EMR.
  • Re-contact and prospective recruitment is available
  • Number of participants enrolled: >2000 as of October 7, 2016

This bioinformatic platform integrates all of the electronic data streams within BCH into one searchable data warehouse, allowing identification of patients with specific diagnoses, laboratory parameters, medication use, and customizable for patient recruitment.

Partners Biorepositories:

The Partners HealthCare Biobank is a large research data and sample repository (MGH and BWH) managed within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine.

  • Samples: DNA, serum and plasma that are linked to EMR data including labs, imaging, ICD-9 codes, survey data (smoking, weight, height, alcohol and other exposures from a self administered standardized questionnaire), and computed clinical phenotypes (based on machine learning algorithms) stored in the Biobank Portal
  • Re-contact is available for 66,030 consented patients as of July 6, 2017
  • Number of samples: 47,399 (15,064 genotyped) as of July 6, 2017
  • Contact for grant proposals, sample/data requests, recruitment

RPDR is a data warehouse of all electronic health record (EHR) data from Massachusetts General Hospital, Brigham and Women’s Hospital, Faulkner Hospital, Spaulding Rehabilitation Hospital, and Newton Wellesley Hospital available for research purposes. RPDR gathers 2.5 billion rows of data from multiple Partners HealthCare System hospitals into a Microsoft SQL Server database. Security and distribution of patient data is controlled and audited according to IRB and HIPAA guidelines; all patient identifiers are encrypted throughout the database to protect privacy. RPDR contains data on 6 million patients including demographics, diagnoses (e.g., ICD-9/10 codes), procedures (e.g., CPT codes), pharmacy data (e.g. RxNorm), inpatient and outpatient encounter information, provider information, laboratory data, imaging and pathology data. Researchers may query the RPDR using an online query tool for aggregate totals of patients in the Biobank that have a particular diagnosis according to ICD-9/ICD-10, medications, other EHR data along with sample availability, genotype results, and validated phenotypes. Faculty at BWH have access to RPDR. Trainees need to be added to a faculty member’s workgroup.  With IRB approval, researchers can download identifiable datasets including medical record numbers and clinical notes.

  • Principal investigator: Dr. Shawn Murphy
  • EMR data available: transfusion, cardiology, contact information, demographics, diagnoses, discharge notes, endoscopy, laboratory tests, allergies, health maintenance, medications, notes, problems, vital signs, medications, microbiology, operative notes, pathology reports, procedures, providers, radiology reports, radiology tests, transfusion, and laboratory results. Images from hospital image repositories can be returned and viewed online.

The Crimson core in the clinical laboratories at Brigham and Women’s Hospital supports prospective collection of discarded blood (leftover from clinical testing) from over 10,000 clinical laboratory samples processed daily at Brigham and Women’s Hospital, Massachusetts General Hospital, and the Dana-Farber Cancer Institute. Crimson enables rapid and cost effective assembly of samples from patients spanning the spectrum of health and disease in human populations.

  • Samples: de-identified samples of discarded specimens from clinical draws of patients identified through RPDR, which can include blood, urine, stool, and surgical specimens.
Back To Top